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Cardiovascular cell-based regenerativemedicine has enjoyed a brief but exciting history. In little over
a decade, multiple hypotheses have risen and fallen, and this work has now triggered a critical recon-
sideration of several long-held cardiovascular paradigms. These and other issues were the focus of
the second Symposium on Cardiovascular Regenerative Medicine, recently held at the NIH-NHLBI in
Bethesda, MD, USA. The meeting served to showcase some of the highlights of the past decade but,
at the same time, sharply underlined the enormity of the task ahead. Collectively, a sense emerged
that researchers in this field are ‘‘digging in for the long haul.’’With so little known about stem cell biology in relation to
the cardiovascular system, the field of cardiovascular re-
generative medicine represents a veritable research ‘‘El
Dorado’’ for those fortunate, or wise enough, to look in
the right places. With the promise of providing a complete
‘‘biologic cure’’ for any number of disease states, re-
searchers in this field have previously been fierce in
defending their hard-won results and ensuing hypotheses.
Perhaps it is the collective point that this field has come to,
or maybe the relatively intimate setting of this meeting, but
the second Symposium on Cardiovascular Regenerative
Medicine, recently held October 1 and 2, 2007 at the
NIH-NHLBI in Bethesda, MD, USA, was certainly notable
for the cooperative and community-like ambience that
prevailed. This was a specialized symposium of modest
size (500 delegates) organized by the NHLBI intramural
program, with additional input from the recently estab-
lished and NHLBI-funded stem cell institutes at Baylor
College of Medicine, Harvard Medical School, and Johns
Hopkins University. The meeting attracted a broad cross-
section of the cardiovascular/stem cell community, includ-
ing basic, physician-scientist, and clinician researchers.
Sessions ranged from the relevant lessons learned from
hematology (particularly, hematopoietic stemcells [HSCs]),
embryonic stem (ES) cells, cardiac stem/progenitor cells,
stem cell niches, vasculogenesis/angiogenesis, cardiac
regeneration, and clinical studies. Aided by an open and
interactive format, the meeting served as a vehicle for
the airing of several critical issues that now confront the
field and, most importantly, what might be done to
address these issues going forward. As evidenced by
the staging of this Symposium on Cardiovascular Regen-
erative Medicine and other initiatives that were outlined
during the sessions, it was pleasing to observe that the
NHLBI appears willing to adopt a role in helping to guide
and support a strategic research endeavor.628 Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc.There were probably few in the audience who were not
familiar with the conference emblem (Figure 1): the classic
scene adapted from the ancient Greek tragedy ‘‘Prome-
theus Bound,’’ attributed to Aeschylus (circa 415 BC). As
the tale goes, the Titan Prometheus provokes the wrath
of Zeus, who in retribution hides fire from humans. Prome-
theus steals fire back and gives it to humans for their use,
a metaphor for the tools for civilization, including science,
medicine, and mathematics. The enraged Zeus chains
Prometheus to a rock, where his regenerating liver is eaten
daily by an eagle.
No Easy Answers
A clear message from the meeting was that the initial
‘‘wave of enthusiasm’’ for cardiac stem cell-based thera-
pies seems to have nearly run its course and that
researchers in this field are now ‘‘digging in for the long
haul.’’ There have been no easy answers and, again,
Mother Nature does not appear to be giving up her secrets
without a struggle. Similarly, the spate of small ‘‘proof-of-
concept’’ clinical trials now seems to be decreasing, as
investigators grapple with the need tomove tomore defin-
itive and appropriately powered studies.
Building on the themes of both the biological complexity
of regenerative systems and the cooperative nature of this
meeting, previously confusing and controversial data
were approached afresh and were not necessarily seen
as the result of improper techniques or poor models. It
was generally recognized that stem cells may be fastidi-
ous in their growth and culture and that experimental
results could easily differ between laboratories. As an
example, it was suggested that even within the same lab-
oratory it can be extremely difficult to reliably derive a spe-
cific progenitor cell population if stringent conditions are
not rigorously and consistently adhered to. The current
trend in the literature of only publishing an abbreviated
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factor that might be easily rectified.
Cardiac Stem Cells
The presence in the adult heart of cardiac stem/progenitor
cells that are potent for one or more of the cardiovascular
lineages seems now beyond doubt (Beltrami et al., 2003;
Laugwitz et al., 2005; Martin et al., 2004; Messina et al.,
2004; Moretti et al., 2006; Oh et al., 2003). In fact, even
the expert observer might be led to believe that there
are multiple populations: for example, those identifiable
using the stem cell markers c-kit, Sca1, Islet1, etc. How-
ever, given the diversity of methods used in their isolation
and characterization, it seems likely that some popula-
tionswill overlap, whereas othersmay be completely inde-
pendent. The following appear to be the critical issues
now at hand. (1) How many cardiac stem and/or progeni-
tor populations truly exist? (2) What are their origins in
development? (3) What is their role in vivo, and what are
the hierarchical, spatial, and functional relationships
between cardiac stem cells and their cellular progeny?
(4) What are their respective potentials that could be har-
nessed to treat cardiovascular disease? (5) How do ische-
mic injury and chronic heart failure affect cardiac stem/
progenitor cell functionality? Much work remains to be
done to adequately delineate the cardiac stem and pro-
genitor populations, and there was clear agreement for
the need to establish a searchable archive detailing the
genetic blueprint and transcriptional profile of these cells.
In addition, an often-mentioned theme at the meeting was
the need for rigorous fate mapping—this is particularly
relevant for tracing endogenous cardiac stem cells into
Figure 1. Drawing Depicting the Ancient Greek Tragedy
‘‘Prometheus Bound,’’ Attributed to Aeschylus, circa 415 BC
In this play, the immortal Titan Prometheus is chained to a rock by Zeus
as punishment for giving the gift of fire to humanity. Among other
tortures, Prometheus was forced to endure daily gouging of his ever-
regenerating intestines, liver, and other organs by an eagle. Repro-
duced with permission from the NIH-NHLBI.their derivative progeny in vivo, because at the current
time, many of the accepted properties of adult stem cells
are merely an extrapolation of their behavior in vitro. We
cannot realistically expect to understand (or harness) car-
diac stem cells until we know where they come from,
where they go, and what they become.
Another key issue in organ-regenerative biology is
whether stem cells resident in an organ at the moment of
their isolation are genuine organ-specific stem cells with
origins in the development of that organ or whether they
enter from other sources such as the bone marrow. Flux
of progenitor-like cells from the bone marrow appears
increasingly important after ischemic injury, not only for
augmentation of new vessel formation but also to activate
local progenitor cell populations (Fazel et al., 2006). With-
out such flux, ischemic cardiac injury progresses to heart
failure much more rapidly.
Further to this, the prospect of yet another cardiac
stem/progenitor cell population derived from the epicar-
dium (Smart et al., 2007) was met with general accep-
tance. The epicardial layer of the heart arises early in
development from a small group of cells called the proepi-
cardial organ, which is embedded within an embryonic
mesenchyme termed the septum transversum. In
mammals, proepicardial cells detach and float freely in
the pericardial fluid before settling on and enveloping the
myocardium. These epicardial cells are known to be the
multipotent precursors of the coronary vascular tree and
interstitial fibroblasts. Current data suggest that these epi-
cardial progenitor cells are the target of Thymosin-b4
(Smart et al., 2007), an actin-binding protein that, curi-
ously, is also secreted. It is upregulated in tumors and
stimulates coronary vasculogenesis during development
and after ischemic injury. Importantly, Thymosin-b4
appears capable of awakening the migratory properties
of even the adult epicardium in vitro. When delivered via
intracardiac or intraperitoneal routes, its ability to protect
against ischemic injury after myocardial infarction (Bock-
Marquette et al., 2004; Srivastava et al., 2007) suggests
that it might target epicardium or its derivatives in the adult
during cardiac infarct repair, a finding of potential clinical
significance.
Endothelial Progenitor Cells
Undoubtedly, the 1997 description of circulating endothe-
lial progenitor cells (EPCs) in the adult human (Asahara
et al., 1997) was a key milestone for cardiovascular regen-
erative medicine. Ten years on, what do we definitively
know about these cells? In a fashion uncannily similar to
the situation with cardiac stem/progenitor cells, several
potential EPC populations appear to exist, no specific
identifying surface antigen has been found, and other
unexpected levels of complexity continue to emerge.
The notion that, in cell therapy, certain cells may augment
the injury-repair process by paracrine cytokine secretion
is a major new paradigm steadily gaining acceptance in
the context of this and other work. Ironically, several cell
populations that may augment new vessel formation via
paracrine functioning may, in fact, not be EPCs or even
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2003). Rather, these paracrine-functioning ‘‘angiogenic’’
(as opposed to angioblast) cells now appear to be closely
related to monocytes/macrophages (Grunewald et al.,
2006). Exactly which cells function in a paracrine manner,
and which in a true progenitor fashion, remains to be
definitively ascertained. The finding that vascular endo-
thelial cells can arise from transplanted common myeloid
progenitor cells or granulocyte/macrophage progenitors
adds further complexity (Bailey et al., 2006). Apart from
the biologic implications, this revelation has left the
EPC-related nomenclature in a state of confusion, as non-
progenitor angiogenic cells are still widely, but incorrectly,
referred to as EPCs. Further, there is no uniform naming
system for the various emerging subtypes of EPCs, and
several delegates mentioned the need for improved clarity
in the current terms that are used in this field. Although
mesenchymal stem cells (MSCs) were not a prominent
topic of this meeting, the prospect that they at least
partially function via paracrine secretion when adminis-
tered as cell therapy was also noted.
The potential site of origin for EPCs and other progenitor
cells that may augment new vessel formation was also
keenly discussed. Initial assumptions that EPCs are solely
bonemarrow derived and related in ontogeny to HSCs are
now being increasingly challenged. Although some EPCs
may emanate from the bone marrow, recent in vitro stud-
ies (Yoder et al., 2007) have now suggested that ‘‘true’’
EPCs (those that act in a progenitor fashion and whose
progeny are endothelial cells) are not exclusively derived
from a common HSC progenitor. Nevertheless, the stem
or progenitor cells that give rise to this subtype of EPC
remain undefined. Intriguingly, tissue-derived cells that
augment new vessel formation may also arise from other
organs, including the liver and small intestine (Aicher
et al., 2007). The relative contribution of the various sour-
ces of EPCs to the apparent circulating pool of these cells
remains an open question.
ES Cells
ES cells were widely discussed during themeeting. Signif-
icant obstacles remain to be overcome before these cells
can be expected to undergo evaluation in clinical cardio-
vascular trials. Further, the multiple regulatory issues that
surround the use of ES cells and their derivatives, includ-
ing the difficulties this potentially raises with respect to
federal funding, continue to heavily influence the research
that is conducted with these cells. Despite this, steady
progress continues to be made toward understanding
the mechanisms/pathways that control ES cells.
A particularly topical issue was the potential of ES cells
to induce teratoma formation when transplanted into the
heart. This may be dependent on many factors, including
the experimental model and the exact nature of the ES cell
population that is administered. Currently, the consensus
view is that the administration of ES-derived cells that are
at least partially committed to a cardiomyocyte fate may
considerably reduce the risk of teratoma formation.
Another concern regarding the use of ES cells to amelio-630 Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc.rate cardiac disease is the very poor survival of these cells
when administered into ischemic or damaged myocardial
tissues. To address both these issues, one group reported
a combined approach of initially driving ES cells toward
a cardiomyocyte phenotype using activin A and BMP-4
and then applying a potent prosurvival cocktail of at least
six growth and antiapoptotic factors (affectionately re-
ferred to as ‘‘the kitchen sink’’) to improve survival of the
ES cell-derived graft (Laflamme et al., 2007).
Given the ethical, immune, and other concerns sur-
rounding the use of human ES cells, the recent break-
through whereby ES-like induced pluripotent stem (iPS)
cells were derived from murine fibroblasts was heralded
as a major turning point in the evolution of the stem cell
field and for cell-based therapies. In this pioneering work
emanating from the laboratory of Dr. Shinya Yamanaka,
pluripotent ES-like cells were derived from murine fibro-
blasts by the retroviral introduction of Oct3/4, Sox2,
c-Myc, and Klf4 (referred to as ‘‘the big four’’ by several
delegates). This and other groups have now further refined
the initial work and provided compelling evidence that
a more stringent selection for iPS cells using expression
of the ES cell pluripotency genes Nanog or Oct4 results
in a more ES cell-like phenotype than was previously
attained. Indeed, this new generation of iPS cells has
been shown to produce germline-competent chimeric
mice after blastocyst injection. These are striking results
that will foster our understanding of how pluripotency in
stem cells is controlled and may lead to an alternative
and ethically nonsensitive route to the generation of pa-
tient-specific ES cell lines. Since this meeting, these
results have been replicated with adult human somatic
cells, albeit without the ultimate proof of germline compe-
tence (Takahashi et al., 2007; Yu et al., 2007). One caveat
is that, in mice generated from iPS cells, the induction of
the c-Myc retrovirus, initially silenced in the iPS cells them-
selves, appears to cause tumor formation in many of the
animals (Okita et al., 2007). However, judging by the
amount of interest that this work received during themeet-
ing, iPS cells and the important issues in stem cell science
that these findings have raised appear likely to be the
focus of significant attention in the coming years.
Signaling Pathways and Cardiac Stem Cell
Regulation
If our overall knowledge of cardiovascular stem and pro-
genitor cells is in its infancy, then our understanding of
the critical but extremely complex signaling and regulatory
pathways that govern these cells is at an even more rudi-
mentary stage. This is perhaps not surprising, given that
cardiac stem/progenitor cells were only described as
recently as 2003 (Beltrami et al., 2003). Transcription fac-
tors/pathways/proteins that received particular attention
at this meeting included Wnts, Sox, Delta-like ligands,
Jagged, Notch, Thymosin-b4 (see above), and Periostin.
Of these, many have particularly complex actions, with
multiple additional up- and downstream players being
implicated. The intricacies of these signaling pathways
are beyond the scope of this report. However, as an
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that certain programs involved in cardiac specification,
such as the canonical Wnt/b-catenin pathway, can exhibit
extremely intricate functioning, such that both the precise
amount and timing of Wnt/b-catenin signaling is critical to
achieve correct cardiac formation (Klaus et al., 2007).
Recent work with Periostin suggests that induction of
DNA synthesis and cytokinesis in otherwise fully differen-
tiated cardiomyocytes may play a role in cardiac repair.
Periostin is an extracellular factor that binds to integrins
and activates the PI3 kinase pathway. It can stimulate
DNA synthesis in 1% of cardiomyocytes in vitro. Long-
term delivery of periostin to the left ventricle after induced
myocardial infarction in rodents induced cytokinesis in
0.1% of cells, increased angiogenesis, and enhanced
cardiac function (Ku¨hn et al., 2007).
Data were also presented during the meeting that impli-
cated a profound but hitherto unappreciated role for
microRNAs in the regulation of germ layer formation in
the ES cell systemand for gene expression, differentiation,
and cell-cycle control in heart and skeletal muscle. In gen-
eral, ES cells are figuring prominently as a system for dis-
secting signaling pathways and stem and progenitor cell
behavior. Of relevance, the geneticmarking of ES cell pop-
ulations to permit lineage tracing during in vitro develop-
ment shows promise as a tool for investigating the early
regulatory events in cardiogenesis (Moretti et al., 2006).
Apart from their potential clinical utility as a cell therapy,
the fact that these cells represent a unique in vitro system
in which pathways can be studied was seen as a further
imperative reason to pursue ES cell-based research.
Transdifferentiation? Plasticity?
The common belief in the phenomenon of transdifferentia-
tion or plasticity, whereby stem/progenitor cells that
exhibit partial lineage commitment are able to biologically
‘‘switch gears’’ and give rise to cells of a different lineage,
appears to have undergone a complete turnaround. Par-
ticularly regarding cells arising from the bone marrow,
transdifferentiation or plasticity was initially thought to be
widely observed in both cell therapy and endogenous set-
tings with respect to cardiac and vascular regeneration
(Orlic et al., 2001a, 2001b). However, several negative
studies then forced a critical reconsideration of this pro-
cess (Alvarez-Dolado et al., 2003; Balsam et al., 2004;
Murry et al., 2004; Nygren et al., 2004). As highlighted in
this meeting, the concept of transdifferentiation or plastic-
ity now appears to be gradually returning to favor (Rota
et al., 2007). Interestingly, and perhaps as a result of this
controversy, speakers generally avoided the terms ‘‘plas-
ticity’’ and ‘‘transdifferentiation,’’ preferring to use expres-
sions such as ‘‘were able to give rise to.’’ Further, during
open discussion, it was evident that the recent work
involving iPS cells (see above) provides strong evidence
that, regardless of its developmental/biological impor-
tance, cellular reprogramming (that is, enforced ex vivo
transdifferentiation) to yield specific stem/progenitor
populations or effector cells is a valid therapeutic goal.Clinical Studies
Not surprisingly, by far the largest of the clinical studies
completed to date, the REPAIR-AMI study (Scha¨chinger
et al., 2006), continued to generate much interest. This
randomized and double-blinded study, in which just over
200 patients recovering from an acute myocardial infarc-
tion received an intracoronary infusion of autologous
bone marrow cells, showed favorable outcomes with
respect to safety, recovery of ventricular contraction,
and the combined clinical endpoint of death, recurrence
of myocardial infarction, and the need for repeat revascu-
larization (Scha¨chinger et al., 2006). This study has now
been bolstered by two recent meta-analyses, which
included the REPAIR-AMI study, and considered a total
of almost 700 (Lipinski et al., 2007) and 1000 (Abdel-Latif
et al., 2007) patients, respectively. Despite subtly different
trial inclusion criteria, both meta-analyses reached the
same conclusions: that the administration of bone mar-
row-derived cell therapy to patients with ischemic heart
disease is safe and efficacious in the short to intermediate
term (Abdel-Latif et al., 2007; Lipinski et al., 2007). Impor-
tantly, long-term safety results are only available from the
initial small phase I studies. As was reiterated at the meet-
ing, this lack of long-term safety results should be borne in
mind, as we are potentially administering cells that may
cause intracardiac tumors or ectopic bone formation
that may not manifest for many years. However, the pos-
sibility of these or other late adverse events was generally
perceived as being unlikely when using unmodified freshly
isolated bone marrow-derived cells, where considerable
safety data are available from earlier hematology studies.
Despite these encouraging results, cell-based clinical
trials continued to have their detractors, with the often-
mentioned concern that the potential mechanisms of ac-
tion of these cell therapies are largely unknown. Also, an
important but unaddressed paradox exists between the
numerous animal studies that showed highly positive
results when cell therapy was administered after myocar-
dial infarction and the far more marginal benefits seen in
clinical trials to date. However, at the meeting, several
clinical investigators set forth the reasonable argument
that the mechanisms of benefit of many conventional
drug therapies remain poorly understood. Therefore,
these investigators maintain that as long as cell therapy
is safe it is reasonable and ethical, if not imperative, to pur-
sue these investigations in cardiac disease patients.
Looking forward, a major challenge facing the field of
cell-based therapies in cardiac patients is appropriate trial
design. Aspects of trial design that were seen as being of
particular importance included appropriate patient selec-
tion, the cell(s) to be administered, method and route of
delivery, adequate study power (number enrolled), ade-
quate length of follow up, the choice of appropriate end
points (including the measurement of ventricular function,
myocardial perfusion, and cardiac muscle mass as appro-
priate to the specific study), and the incorporation of valid
safety outcomes. Although personal opinions varied, as a
broad generalization, most perceived the need for a com-
bination of smaller mechanistic clinical studies and muchCell Stem Cell 1, December 2007 ª2007 Elsevier Inc. 631
Cell Stem Cell
Meeting Reportlarger outcome-based trials that are powered to prove or
disprove efficacy. Themix of large multicenter and smaller
single-institution clinical studies that are either currently
underway or in the final planning stages appears to gener-
ally reflect this sentiment. The prospective identification of
specific patient populations that may especially benefit
from cell-based therapies may also help to achieve more
profound clinical effects.
Conclusions
It is no simple task to reconcile the significant clinical
implications of regenerative cell therapy, with the large
amount of investigation that remains to be carried out to
achieve this goal. With this research being of such
a high public profile, the pressure to achieve tangible
clinical benefits is great, and it becomes evenmore imper-
ative that this work be conducted in a methodical and rig-
orous manner. The strengthening of research ties and the
sharing of information, as seen at this meeting, can only
increase our collective capacity to address some of these
issues and to seek answers to the major unanswered sci-
entific questions that we now face.
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